| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ea17ba87480b776cce77451f86b25bb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D305-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D305-14 |
| filingDate |
2020-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a9da7515308b4322b7c2cfebb6eac94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0d2021ef068e4752a2210d1d1ee0ebb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b617a29f87b0fdfc12a5d7f3f8493f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bd2e61f5c3b4ee3faee4b8f2a6536ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e55214085d7b15776fe6088914ffdaec |
| publicationDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020249507-A1 |
| titleOfInvention |
Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it |
| abstract |
An anhydrous, crystalline form of Cabazitaxel [Form (H-1)] is herein disclosed. Form H-1 shows a13C SS-NMR spectrum featuring one single polymorph and showing the same advantages as known form H with respect to known Form D in terms of stability to humidity and impurities A, B and C. A process for the obtainment of Form H-1 is also herein disclosed. |
| priorityDate |
2019-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |